AR065796A1 - Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina - Google Patents
Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidinaInfo
- Publication number
- AR065796A1 AR065796A1 ARP080101144A ARP080101144A AR065796A1 AR 065796 A1 AR065796 A1 AR 065796A1 AR P080101144 A ARP080101144 A AR P080101144A AR P080101144 A ARP080101144 A AR P080101144A AR 065796 A1 AR065796 A1 AR 065796A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorder
- depression
- addition salt
- salt
- acid
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- -1 4-METHYLPHENYL Chemical class 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000012669 liquid formulation Substances 0.000 title 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- CVASBKDYSQKLSO-UHFFFAOYSA-N Tedatioxetine Chemical class C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 CVASBKDYSQKLSO-UHFFFAOYSA-N 0.000 abstract 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 abstract 2
- 229960005261 aspartic acid Drugs 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 235000013922 glutamic acid Nutrition 0.000 abstract 2
- 239000004220 glutamic acid Substances 0.000 abstract 2
- 229960000448 lactic acid Drugs 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000025748 atypical depressive disease Diseases 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000025307 bipolar depression Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicacion 1: Una formulacion farmacéutica líquida que comprende una sal de 4-[2-(4-metilfenilsulfanil)fenil]piperidina seleccionada entre la sal de adicion de ácido DL-láctico, la sal de adicion del ácido glutárico, la sal de adicion del ácidoL-aspártico y la sal de adicion del ácido glutámico. Reivindicacion 15: Una sal de 4-[2-(4-metilfenilsulfanil)fenil]piperidina seleccionada entre la sal de adicion del ácido DL-láctico, la sal de adicion del ácido glutárico, la sal de adicion delácido L-aspártico y la sal de adicion del ácido glutámico para utilizar en el tratamiento de una enfermedad seleccionada entre trastornos del estado de ánimo, trastorno depresivo mayor, trastorno de ansiedad generalizada, depresion atípica,depresion bipolar, trastorno de ansiedad social, trastorno obsesivo compulsivo, trastorno de pánico, trastorno de estrés post-traumático, abuso, trastorno alimenticio, trastorno del sueno, enfermedad de Alzheimer, demencia, dolor cronico, depresionasociada con deterioro cognitivo, depresion asociada con psicosis, deterioro cognitivo en la esquizofrenia, depresion o ansiedad asociada con dolor, alteraciones del comportamiento en las personas mayores de edad, ADHD, melancolía, depresionresistente al tratamiento o depresion con síntomas residuales, donde dicha sal está en una formulacion farmacéutica líquida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700423 | 2007-03-20 | ||
| PCT/DK2007/050076 WO2007144006A1 (en) | 2006-06-16 | 2007-06-15 | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| DKPA200701790 | 2007-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065796A1 true AR065796A1 (es) | 2009-07-01 |
Family
ID=39327217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101144A AR065796A1 (es) | 2007-03-20 | 2008-03-19 | Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20100105730A1 (es) |
| EP (2) | EP2129377B1 (es) |
| JP (1) | JP5301474B2 (es) |
| KR (1) | KR20090130000A (es) |
| AR (1) | AR065796A1 (es) |
| AT (1) | ATE526966T1 (es) |
| AU (1) | AU2008228637B2 (es) |
| BR (1) | BRPI0808820A2 (es) |
| CA (1) | CA2684592C (es) |
| CL (1) | CL2008000797A1 (es) |
| CO (1) | CO6220958A2 (es) |
| CY (1) | CY1112285T1 (es) |
| DK (1) | DK2129377T3 (es) |
| EA (1) | EA019695B1 (es) |
| ES (1) | ES2373275T3 (es) |
| HR (1) | HRP20110844T1 (es) |
| IL (1) | IL200959A (es) |
| MX (1) | MX2009009388A (es) |
| MY (1) | MY148695A (es) |
| NZ (1) | NZ579717A (es) |
| PL (1) | PL2129377T3 (es) |
| PT (1) | PT2129377E (es) |
| RS (1) | RS52050B (es) |
| SI (1) | SI2129377T1 (es) |
| TW (1) | TWI405588B (es) |
| WO (1) | WO2008113358A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| WO2008151632A1 (en) * | 2007-06-15 | 2008-12-18 | H.Lundbeck A/S | 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs) |
| DK2421534T3 (da) | 2009-04-24 | 2014-10-13 | Lundbeck & Co As H | Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin |
| KR101820181B1 (ko) | 2010-04-30 | 2018-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 장용성 정제 |
| BR112012027782A2 (pt) | 2010-04-30 | 2016-08-02 | Takeda Pharmaceutical | tablete entérico |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10163326A1 (de) | 2001-07-30 | 2003-02-27 | Disetronic Licensing Ag | Verabreichungsgerät mit Dosiervorrichtung |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| EP1446328B1 (en) | 2001-10-16 | 2017-05-31 | Medical Instill Technologies, Inc. | DISPENSER WITH SEALED CHAMBER AND ONE−WAY VALVE FOR PROVIDING METERED AMOUNTS OF SUBSTANCES |
| DE10202367A1 (de) | 2002-01-23 | 2003-09-25 | Duerr Dental Gmbh Co Kg | Applikator für flüssige oder viskose Substanzen |
| HRP20080478T3 (hr) * | 2003-04-04 | 2009-02-28 | H. Lundbeck A/S | Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina |
| AU2007260356B2 (en) * | 2006-06-16 | 2013-01-24 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| KR101367136B1 (ko) * | 2007-07-27 | 2014-02-25 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 및 이의 제조 방법 |
-
2008
- 2008-03-06 TW TW097107758A patent/TWI405588B/zh not_active IP Right Cessation
- 2008-03-14 DK DK08715616.2T patent/DK2129377T3/da active
- 2008-03-14 US US12/527,907 patent/US20100105730A1/en not_active Abandoned
- 2008-03-14 EP EP08715616A patent/EP2129377B1/en active Active
- 2008-03-14 NZ NZ579717A patent/NZ579717A/en not_active IP Right Cessation
- 2008-03-14 CA CA2684592A patent/CA2684592C/en not_active Expired - Fee Related
- 2008-03-14 PT PT08715616T patent/PT2129377E/pt unknown
- 2008-03-14 MY MYPI20093675A patent/MY148695A/en unknown
- 2008-03-14 RS RS20110545A patent/RS52050B/sr unknown
- 2008-03-14 MX MX2009009388A patent/MX2009009388A/es active IP Right Grant
- 2008-03-14 PL PL08715616T patent/PL2129377T3/pl unknown
- 2008-03-14 BR BRPI0808820-9A patent/BRPI0808820A2/pt not_active IP Right Cessation
- 2008-03-14 HR HR20110844T patent/HRP20110844T1/hr unknown
- 2008-03-14 AU AU2008228637A patent/AU2008228637B2/en not_active Ceased
- 2008-03-14 ES ES08715616T patent/ES2373275T3/es active Active
- 2008-03-14 EA EA200970869A patent/EA019695B1/ru not_active IP Right Cessation
- 2008-03-14 AT AT08715616T patent/ATE526966T1/de active
- 2008-03-14 JP JP2009553909A patent/JP5301474B2/ja not_active Expired - Fee Related
- 2008-03-14 SI SI200830435T patent/SI2129377T1/sl unknown
- 2008-03-14 KR KR1020097019519A patent/KR20090130000A/ko not_active Abandoned
- 2008-03-14 EP EP11177654A patent/EP2388004A1/en not_active Withdrawn
- 2008-03-14 WO PCT/DK2008/050062 patent/WO2008113358A1/en not_active Ceased
- 2008-03-19 CL CL200800797A patent/CL2008000797A1/es unknown
- 2008-03-19 AR ARP080101144A patent/AR065796A1/es unknown
-
2009
- 2009-09-15 IL IL200959A patent/IL200959A/en not_active IP Right Cessation
- 2009-09-16 CO CO09100112A patent/CO6220958A2/es not_active Application Discontinuation
-
2011
- 2011-12-02 CY CY20111101195T patent/CY1112285T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076400A1 (es) | Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente | |
| CL2008003363A1 (es) | Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual. | |
| AR065796A1 (es) | Formulaciones liquidas de sales de 4-(2-(4-metilfenilsulfanil)fenil) piperidina | |
| AR065798A1 (es) | Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina | |
| Proserpio et al. | Integrating sleep and Alzheimer’s disease pathophysiology: hints for sleep disorders management | |
| ATE522538T1 (de) | Substituierte spirocyclische piperidinderivate als histamin-3-(h3)rezeptorliganden | |
| Park et al. | The analysis of risk factors influencing adolescent suicidal ideation in a multicultural family-based on the 2012 Korean youth health risk behavior on-line survey | |
| AR098599A2 (es) | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo | |
| EA201170352A1 (ru) | Способы лечения расстройств цнс | |
| Andreasen et al. | Nicotine reverses anhedonic-like response and cognitive impairment in the rat chronic mild stress model of depression: comparison with sertraline | |
| de la Tremblaye et al. | Rehabilitative success after brain trauma by augmenting a subtherapeutic dose of environmental enrichment with galantamine | |
| ربيعي et al. | Relationship between components of cognitive emotion regulation and anxiety disorders in child and adolescent | |
| Waltzman et al. | Who is publishing in facial cosmetic surgery? A citation analysis across specialties over five decades | |
| Upfal | Jane Austen’s lifelong health problems and final illness: New evidence points to a fatal Hodgkin’s disease and excludes the widely accepted Addison’s | |
| Faruqui et al. | A study of the correlation between smartphone usage and dry eye in medical students at a tertiary care center | |
| Sogolitappeh et al. | Effectiveness of group life skills training on decreasing anxiety and depression among heart patients, after bypass surgery | |
| Pontoski et al. | Psychotherapy for social anxiety disorder. | |
| Lunde | The Psychology of Ageing | |
| AR056056A1 (es) | Asociacion entre la agomelatina y un inhibidor de la recaptacion de la noradrenalina y las composiciones farmaceuticas que las contienen | |
| Bricio-Moreno et al. | Using Multiphoton Intravital Microscopy to Study Neutrophil Transmigration and Blood− Brain Barrier Permeability in a Mouse Model of Herpes Simplex Virus Encephalitis | |
| van der Fluit et al. | Williams Syndrome | |
| Fallon et al. | Illness Anxiety Disorder, Somatic Symptom Disorder, and Body Dysmorphic Disorder | |
| Getz | Brain reserve capacity | |
| Cook | Engaging with neuroscience nurses in Northern Ireland. | |
| van der Fluit et al. | Williams Syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |